Rapamycin triggersa facultative diapause-like state that mimics famine signaling without depleting energy stores, extending lifespan via stress‑pathway activation rather than true metabolic rejuvenation

Hypothesis

Rapamycin does not extend lifespan by repairing aging damage; instead it pharmacologically induces a facultative diapause‑like state that activates conserved stress‑response programs evolved for surviving transient famine. This state mimics the signaling periphery of caloric restriction (CR) without reproducing CR’s deep metabolic re‑programming, so longevity arises from pathway modulation rather than from genuine cellular rejuvenation.

Mechanistic Rationale

• Signal mimicry, not metabolic depletion – CR lowers intracellular ATP/AMP ratio, depletes glycogen and lipid droplets, and drives a coordinated shift from glycolysis to β‑oxidation and autophagy [[https://academic.oup.com/biomedgerontology/article/73/1/29/3063959]]. Rapamycin reduces mTORC1 activity and up‑regulates autophagy but leaves ATP levels, glycogen, and lipid stores largely unchanged [[https://pmc.ncbi.nlm.nih.gov/articles/PMC9982835/]]. The drug therefore reproduces the signaling arm (AMPK‑ULK1, TFEB nuclear translocation) while bypassing the energetic arm that forces cells to catabolize reserves.
• Facultative diapause analogy – Many organisms enter a reversible dormancy (e.g., dauer, adult reproductive diapause) when nutrients fall, characterized by heightened stress resistance, reduced growth, and preserved energy stores [[https://www.science.org/doi/10.1126/sciadv.adw8410]]. Rapamycin‑treated mice show comparable increases in stress‑resistance markers (HSP70, SOD2) and unchanged adipose mass, fitting a diapause‑like physiology.
• Immune‑mediated disease mitigation – Chronic rapamycin reshapes gut immunity and reduces inflammaging [[https://pubmed.ncbi.nlm.nih.gov/26315673/]], which can extend lifespan independently of damage repair. This aligns with a diapause strategy where investment shifts from reproduction to survival and pathogen defense.

Testable Predictions

1. Metabolomic signature – Targeted LC‑MS of liver from rapamycin‑treated, CR, and control mice will reveal that rapamycin reproduces the CR‑associated increase in autophagy‑related metabolites (e.g., spermidine, succinate) but fails to lower hepatic glycogen, triglycerides, or NAD⁺/NADH ratio to CR levels. Falsification: if rapamycin matches CR’s glycogen/lipid depletion, the impersonation claim weakens.
2. Genetic epistasis – In mice with liver‑specific knockout of Atg5 (autophagy deficient) or Foxo3 (stress‑transcription factor), rapamycin will lose its lifespan‑extending effect, whereas CR will retain partial extension via other pathways (e.g., IGF‑1 reduction). Falsification: if rapamycin still extends lifespan in autophagy‑deficient mice, the diapause‑like mechanism is insufficient.
3. Physiological read‑out of diapause – Measure circulating cortisol‑like stress hormones and expression of diapause‑associated genes (e.g., dpydh, hsp90aa1) after 4 weeks of rapamycin vs. CR. Prediction: rapamycin elevates these markers to CR‑like levels without changing body weight or fat mass. Falsification: no increase in diapause markers.
4. Late‑onset efficacy – Administer rapamycin at 20 months (as in prior studies) and compare to initiating CR at the same age. Prediction: rapamycin maintains ≥50 % of its maximal lifespan benefit when started late, whereas CR shows <20 % benefit. Falsification: if late‑start CR matches rapamycin, the impersonation hypothesis loses its age‑specific advantage.

Potential Confounds and Controls

• Drug off‑target effects – Use everolimus (another mTORC1 inhibitor) and a genetic Raptor heterozygous mutant to confirm that observations are mTORC1‑specific.
• Compensatory feeding – Pair‑feed rapamycin‑treated mice to control for subtle changes in food intake that could mimic CR.
• Microbiome contribution – Germ‑free or antibiotic‑treated cohorts will test whether immune‑mediated benefits depend on microbiota shifts.

If these experiments confirm that rapamycin reproduces CR’s stress‑signaling landscape without depleting energy stores, extends life mainly via autophagy‑ and FOXO‑dependent pathways, and retains efficacy when started late, the hypothesis that mTOR inhibition impersonates a harder life rather than genuinely repairing aging damage gains strong mechanistic support. Conversely, demonstration of equivalent metabolic re‑programming or autophagy‑independent longevity would falsify the impersonation model and favor a damage‑repair interpretation.